Funding
Funding not disclosed
Founders
Product
Problem
Identifying reliable biomarkers and designing targeted therapeutics for precision medicine is time‑consuming and costly, often hindered by fragmented data, limited predictive models, and low success rates in preclinical development.
Solution
DeepTarget Biotherapeutics addresses this gap with its DTB.AI™ platform, a proprietary agentic bio‑AI system that combines a large reasoning model, inverse reinforcement learning, reinforcement learning, and a human‑in‑the‑loop feedback loop. The platform accelerates biomarker discovery, validation, and therapeutic design by integrating extensive biological datasets and expert knowledge to generate high‑confidence targets. It then leverages these insights to engineer three classes of precision therapeutics: TSI™ bio‑ADCs (bi‑/tri‑specific antibody‑drug conjugates), T‑TCE™ next‑generation T‑cell engagers, and TSIM™ innovative immune modulators. By automating and optimizing the end‑to‑end pipeline, DeepTarget reduces development timelines and improves the probability of clinical success for preclinical programs.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking AI‑enhanced biomarker discovery and rapid development of targeted ADCs, T‑cell engagers, and immune modulators for oncology and immunotherapy pipelines.
Features
- Large Reasoning Model (LRM) that processes multi‑omics and clinical data to identify actionable biomarkers
- Inverse reinforcement learning and reinforcement learning framework that iteratively refines target predictions with expert feedback
- Human‑in‑the‑loop architecture ensuring domain expertise guides AI‑driven hypothesis generation
- Automated design of targeted bio‑ADCs (TSI™) with bi‑/tri‑specificity for precise tumor antigen engagement
- Generation of next‑generation T‑cell engagers (T‑TCE™) optimized for potency and safety profiles
- Creation of novel immune modulators (TSIM™) to modulate the tumor microenvironment
- Integrated preclinical workflow that links biomarker discovery directly to therapeutic candidate generation